Re-irradiation of recurrent lung tumours: Associations between dose and 2-year survival
OS<sub>2-yr</sub> following re-RT of recurrent NSCLC is significantly associated with retreatment dose. A reasonable target dose for re-RT is EQD2s > 50 Gy<sub>10</sub> with survival rates continuing to increase to 85 Gy<sub>10</sub>.
Authors
- Stephen Harrow
- Anthony J. Chalmers (ORCID: https://orcid.org/0000-0002-1746-7278)
- John D. Fenwick
- R. Rulach
Institutions
- Western General Hospital (GB)
- Edinburgh Cancer Research (GB)
- University of Oxford (GB)
- CRUK/MRC Oxford Institute for Radiation Oncology (GB)
- University College London (GB)
- University of Glasgow (GB)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.ctro.2025.101036
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beatson Cancer Charity
- Cancer Research UK